BioSpace News Archive

Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that the United States Patent and Trademark Office has issued a patent that will strengthen its ability to deliver a tumor-informed, high-definition, molecular residual disease (MRD) assay to market.

Stevanato Group S.p.A. announced the pricing of its upsized underwritten public offering of an aggregate of 12,700,000 of its ordinary shares at a public offering price of $26.00 per share.

CosmosID, a renowned microbiome analytics company, is thrilled to announce a groundbreaking collaboration with Resilient Biotics, a leading microbiome platform company with a pipeline of products for maintaining respiratory tract health.

On the evening of March 21st, OcuMension Therapeutics Co., Ltd. disclosed its 2023 annual performance report.

(“BioHarvest” or the “Company”), a biotechnology company pioneering its patented Botanical Synthesis technology platform, today announced the appointment of experienced life sciences executive Anna Tenstam as VP of Business Development,

MIRA Pharmaceuticals Inc. proudly announces the appointment of distinguished pharmaceutical executive Dr. Itzchak Angel as its new Chief Scientific Advisor.

Northwest Biotherapeutics announced today that it has appointed Mr. Pat Sarma to its Board of Directors effective March 18, 2024.

Nanodropper, Inc., an ophthalmic device company that created the eyedrop volume-reducing Nanodropper® Adaptor, announced today that its clinical trial “An Evaluation of the Efficacy and Safety of Timolol Maleate 0.5% Microdrops Administered with the Nanodropper” was published in the journal Ophthalmology.

Medtronic (NYSE:MDT), the global leader in healthcare technology, today announced that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has affirmed the validity of claims in two of its patents in an ongoing patent infringement lawsuit filed by Medtronic against Axonics over sacral neuromodulation (SNM) technologies.

Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release its financial results for the fourth quarter and full year ended December 31, 2023, before the open of the financial markets on Monday, April 1, 2024.